What Happened?
Shares of medical technology company Enovis Corporation (NYSE: ENOV) jumped 15% in the afternoon session after the Centers for Medicare & Medicaid Services reversed previously announced reimbursement cuts for the company's non-invasive bone growth stimulators.
The decision marks a significant rebound for the stock, which had declined 12% during a prior session. The positive move was also supported by broader strength in the healthcare sector. According to reports, healthcare was the top-performing sector in the S&P 500 after a soft June jobs report dampened expectations for interest rate hikes, boosting defensive sectors.
Is now the time to buy Enovis? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Enovis’s shares are very volatile and have had 27 moves greater than 5% over the last year. But moves this big are rare even for Enovis and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 4 months ago when the stock gained 12.6% on the news that the company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026.
While the company's revenue of about $576 million for the quarter fell short of expectations, its adjusted earnings per share of $0.95 comfortably beat analyst estimates. The key driver for the stock's jump appeared to be the company's positive outlook.
For 2026, Enovis forecasted full-year adjusted earnings per share to be in the range of $3.52 to $3.73. The midpoint of this forecast was significantly higher than what analysts had previously projected, signaling to investors that management expected strong profitability in the year ahead. This encouraging profit outlook overshadowed the slight revenue miss from the previous quarter.
Enovis is down 3% since the beginning of the year, and at $25.71 per share, it is trading 28.5% below its 52-week high of $35.94 from July 2025. Investors who bought $1,000 worth of Enovis’s shares 5 years ago would now be looking at only $187.58.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
